Novo Nordisk A/S (NYSE:NVO) announced a Semi-Annual dividend on Friday, August 9th, NASDAQ reports. Investors of record on Monday, August 19th will be given a dividend of 0.318 per share on Tuesday, August 27th. The ex-dividend date is Friday, August 16th.

Novo Nordisk A/S has raised its dividend payment by an average of 19.3% annually over the last three years. Novo Nordisk A/S has a dividend payout ratio of 44.0% indicating that its dividend is sufficiently covered by earnings. Equities analysts expect Novo Nordisk A/S to earn $2.81 per share next year, which means the company should continue to be able to cover its $1.11 annual dividend with an expected future payout ratio of 39.5%.

Shares of NYSE NVO traded down $1.05 during midday trading on Wednesday, hitting $50.81. The stock had a trading volume of 197,463 shares, compared to its average volume of 1,426,194. The firm’s 50 day moving average is $49.53. The stock has a market cap of $123.15 billion, a P/E ratio of 20.16, a P/E/G ratio of 2.30 and a beta of 0.60. Novo Nordisk A/S has a 52 week low of $41.23 and a 52 week high of $52.83. The company has a current ratio of 0.96, a quick ratio of 0.66 and a debt-to-equity ratio of 0.07.

Several research analysts have recently weighed in on NVO shares. Pareto Securities raised shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Monday, August 5th. UBS Group reissued a “buy” rating and set a $355.00 price objective on shares of Novo Nordisk A/S in a report on Wednesday, June 19th. Deutsche Bank cut shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating and set a $52.42 price objective for the company. in a report on Thursday, June 20th. Zacks Investment Research raised shares of Novo Nordisk A/S from a “sell” rating to a “hold” rating and set a $50.00 price objective for the company in a report on Monday, July 15th. Finally, Barclays raised shares of Novo Nordisk A/S from an “underweight” rating to an “equal weight” rating and set a $51.85 price objective for the company in a report on Tuesday, June 11th. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating and six have issued a buy rating to the company. The company has an average rating of “Hold” and an average target price of $111.58.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, a healthcare company, engages in the development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral anti-diabetic products, obesity, and other chronic diseases.

Featured Story: After-Hours Trading

Dividend History for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.